<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:10pt Times New Roman, serif; }
 .font2 { font:15pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font2">JPMorgan</span></p>
<p><span class="font0" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.2hao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.2hao@jpmorgan.com</span></a></p>
<p><span class="font1">Inc.) produces and sells blood transfusion devices and surgical consumables, and premium imported medical equipment.</span></p>
<p><span class="font1">Fosun is also the single largest shareholder of Saladax Biomedical, which has exclusive distribution and manufacturing rights in China. Alma Lasers, a holding company of Fosun Pharma, is a leading global medical and aesthetic device manufacturer with business covering more than 60 countries including US, Germany and Brazil etc. It has a 15% market share in global high-end aesthetic energy based device segment and is the market leader in China.</span></p>
<p><span class="font1">In 1H16, the revenue from this segment increased by 19% to RMBL315mn. This increase was due to a 31% increase in the revenue from distribution of medical devices and medical diagnosis. This increase was in part due to an increase in the sales volume of Da Vinci surgical robots. Also, the revenue from Alma Lasers increased by 16%. Revenue from Medical Diagnosis and medical devices amounted to RMB 1,716 million, a Y-O-Y increase of 14.7% and accounting for 17.95% of overall sales, up from 16.2% in the year before. The increase in revenue of distribution business was mainly due to an increase in sales of consumables brought by the accelerated sales of Da Vinci surgical robotic system and the increased volume of surgeiy.</span></p>
<p><a name="bookmark0"></a><span class="font1" style="font-weight:bold;"><a name="bookmark1"></a>Healthcare Sendees</span></p>
<p><span class="font1">Fosun owns and operates a series of high-end hospitals in Tier I and Tier II cities. It entered the healthcare sendee market in 2010 by acquiring 18.5% stake in Chindex International Inc. which owned United Family healthcare, an International and premium healthcare sendee brand. The group has also invested in Anhui Jimin Cancer Hospital, Guangji Hospital, Zhongwu Hospital and Chacheng Hospital to enter the specialist and integrated healthcare market. Further, in 2015, Qingdao United Family Hospital commenced operations and in pursuit of overseas opportunities acquired 30% equity interest in Sovereign Medical sendees Inc., a day surgeiy center, in United States.</span></p>
<p><span class="font1">In 1H16, revenue from this segment increased by 12% to RMB752mn. The number of beds in the 5 biggest hospitals of the group increased to 3,018. Revenue from Healthcare sector amounted to RMB 1,377 million representing a Y-O-Y increase of 16.1% and accounting for 11.0% of the overall revenue up from 9.93% in the previous year. Healthcare sendee sector is projected to bring in sizeable profits for the group in the future, so being one of the first entrants of this market; Fosun is well positioned to take advantage of the position.</span></p>
<p><span class="font0" style="font-weight:bold;">26</span></p>
</body>
</html>